Nursing Cancer Chemotherapy Pharmacology Practice Questions: Chapter 33-34 Protein Tyrosine Kinase Inhibitors of VEGFR
and other receptors: lenvatinib (Lenvima)
Click on the correct answer.
Lenvatinib inhibits differentiated thyroid cancer tumor growth because of the drug's antiangiogenic activity.
True
False
Lenvatinib enzyme inhibitory profile/profiles:
Inhibits protein kinase activities of VEGFR-1 (Vascular Endothelial Growth Factor)
Inhibits protein kinase activities of VEGFR-2 (Vascular Endothelial Growth Factor)
Inhibits protein kinase activities of VEGFR-3. (Vascular Endothelial Growth Factor)
A & B
B & C
A & C
A, B & C
Lenvatinib inhibits which one(s) of the following receptor kinases involved in pathologic angiogenesis and cancer progression.
Recurrent or metastatic thyroid cancer (differentiated).
In therapeutic combination with everolimus in treating patients with advanced renal cell carcinoma (RCC).
Both
Combination of everolimus
(mTOR inhibitor) and lenvatinib increased antiangiogenic/antitumor activity compared to either drug used alone by:
Reducing endothelial cell division
Reducing tube formation
Decreasing VEGF signaling
A & B
B & C
A & C
A, B & C
Lenvatinib pharmacodynamic/kinetics:
Oral absorption
High-protein binding (about 98%)
Both
Neither
Lenvatinib pharmacodynamic/kinetics: Metabolism
Hepatic metabolism through CYP3A isoforms
Metabolism by aldehyde oxidase.
Both
Neither
Lenvatinib adverse effects (major):
Hypertension
Hemorrhagic events
Both
Neither
Lenvatinib administration in pregnancy may result in fetal harm. Therefore females of reproductive potential should employ effective contraception not only during lenvatinib treatment but for at least a month following completion of treatment.
True
False
With oral administration, lenvatinib exhibits some emetic properties; therefore antiemetics may be appropriate to limit nausea and vomiting.
